Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06987968 · ClinicalTrials.gov registry record · Phase 2
A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy
A Phase 2 study, sponsored by Genfit.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT06987968: Clinical Trial Phase 2 study, sponsored by Genfit.
NCT06987968 is a Phase 2 study that was terminated before completion, run by Genfit. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06987968, a Phase 2 study, was terminated before completion, sponsored by Genfit.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard of Care Alone in Patients with Overt Hepatic Encephalopathy
Interventions
- DRUG SOC
- DRUG VS-01 on top of SOC (Active Treatment Group)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2025-08-25 |
| Est. Completion | 2025-09-15 |
| Phase | Phase 2 |
Why NCT06987968 stopped before completion
NCT06987968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which SOC is the first listed.
NCT06987968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06987968 about?
NCT06987968 is a clinical study titled "A Study to See if an Investigational Medicine Called VS-01 Can Help and How Safe it is in the Treatment of Patients With Overt Hepatic Encephalopathy". A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care versus Standard of Care Alone in Patients with Overt Hepatic Encephalopathy
What is the current status of trial NCT06987968?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2025-08-25. Estimated completion is 2025-09-15.
What interventions are being tested in trial NCT06987968?
The interventions under investigation include: SOC (DRUG), VS-01 on top of SOC (Active Treatment Group) (DRUG).
Who is sponsoring clinical trial NCT06987968?
This trial is sponsored by Genfit, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06987968's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI